Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome

N/ACompletedNCT02060409

Samsung Medical Center58 enrolled

Overview

In the era of hypomethylating agent in MDS treatment, the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.

A number of studies have tried to investigate clinical impact of mutations in spliceosomal machinery genes in MDS but they failed to demonstrate a consistent prognostic relevance. Moreover, the clinical impact of these mutations on the outcomes of hypomethylating agent treatment in MDS has never been explored yet. The investigators investigated the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Myelodysplastic Syndrome

Interventions

spliceosomeGENETIC

spliceosome mutations

Eligibility

Sex: ALLMin age: 17 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * de novo MDS patients were included in the study who had received 1st line decitabine treatment and had adequate genomic DNA from pretreated bone marrow samples Exclusion Criteria: * therapy-related MDS

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

overall survival

Time frame: Two years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.